drug
as of 2026-07-01Bitopertin
bitopertin [RO4917838] level 1bitopertin [RO4917838] level 2bitopertin [RO4917838]
at a glance
small molecule
Pre-approval / investigational in the US
Developed by Hoffmann-La Roche
5 trials in the graph
Synthesized from structured facts only — each point cited above.
Mechanism & identity
Modality
small molecule
Indications
Investigational (via trials)
Trials
5
A Study of RO4917838 (Bitopertin) in Patients With Sub-optimally Controlled Symptoms of Schizophrenia (WN25305)
NCT01235559Phase 3Completed
A Study of RO4917838 (Bitopertin) in Patients With Sub-optimally Controlled Symptoms of Schizophrenia (WN25306)
NCT01235585Phase 3Completed
A Study of RO4917838 (Bitopertin) in Patients With Persistent, Predominant Negative Symptoms of Schizophrenia (WN25309)
NCT01192906Phase 3Completed
A Study to Evaluate Efficacy and Safety of Bitopertin in Participants With Persistent, Predominant Negative Symptoms of Schizophrenia
NCT01192880Phase 3Completed
A Study of RO4917838 (Bitopertin) in Patients With Acute Exacerbation of Schizophrenia
NCT01234779Phase 2Completed
Facts & assertions
0 sourced
No assertions recorded for this entity.
relationships
The graph out of here
developer
company
trial
indication
indication
indication